Abstracts tagged "Lupus nephritis"

Abstract Number: 1505 • ACR Convergence 2021
Inflammatory Dendritic Cell and Th17 Polarization in Mouse Model of Lupus Nephritis
Latha Prabha Ganesan¹, Noushin Saljoughian¹, James Turman¹, Murugesan Rajaram¹, Brad Rovin², Wael Jarjour¹ and Samir Parikh², ¹Ohio State University, Columbus, OH, ²Ohio State University Wexner Medical Center, Columbus, OH
Background/Purpose: We have recently identified inflammatory dendritic cells (InfDC) in human lupus kidneys. These cells are over expressed in LN patients compared to healthy controls.…
Abstract Number: 0353 • ACR Convergence 2021
Soluble Urine ALCAM Reflects Renal Disease Activity in Lupus Nephritis
Dalena Chu¹, Noa Schwartz², Jeanette Ampudia¹, Joel Guthridge³, Judith James³, Jill Buyon⁴, Stephen Connelly¹, Maple Fung⁵, Cherie Ng¹, Chandra Mohan⁶ and Chaim Putterman⁷, ¹Equillium, Inc., La Jolla, CA, ²Albert Einstein College of Medicine/Montefiore Medical Center, New York, NY, ³Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴NYU School of Medicine, New York, NY, ⁵Equillium, Inc., San Diego, CA, ⁶University of Houston, Houston, TX, ⁷Albert Einstein College of Medicine, Bronx, NY
Background/Purpose: Lupus nephritis (LN) is a leading cause of morbidity and mortality in systemic lupus erythematosus (SLE) patients. While LN pathogenesis has yet to be…
Abstract Number: 1271 • ACR Convergence 2021
Healthcare Resource Utilization and Costs Associated with Systemic Lupus Erythematosus After Diagnosis of End-Stage Kidney Disease: Evidence from Two United States Databases
Shirley Huang¹, Amy Guisinger² and Christopher Bell¹, ¹GlaxoSmithKline, Research Triangle Park, NC, ²US Value, Evidence and Outcomes, GlaxoSmithKline, Research Triangle Park, NC
Background/Purpose: Approximately 40% of patients with systemic lupus erythematosus (SLE) develop lupus nephritis (LN), of whom up to 20% may progress to end-stage kidney disease…
Abstract Number: 1627 • ACR Convergence 2021
Long Term Follow-Up of Patients with Childhood-Onset Lupus Nephritis After Transition to Adult Care
Dahima Cintrón¹, Suheiry Márquez¹ and Luis Vilá², ¹University of Puerto Rico Medical Sciences Campus, San Juan, PR, ²University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico
Background/Purpose: Approximately 20% of patients with systemic lupus erythematosus (SLE) are diagnosed before 18 years of age. Pediatric patients have a worse disease course when…
Abstract Number: 0356 • ACR Convergence 2021
The Role of Neutrophils in the Clinical Severity of Lupus Nephritis Patients with Concurrent Skin Disease
Lais Osmani, Sicong Shan, Zoe Chafouleas, Jason Pettus and Sladjana Skopelja-Gardner, Dartmouth Hitchcock Medical Center, Lebanon, NH
Background/Purpose: Skin disease affects >80% of lupus patients and has been linked to lupus nephritis (LN) flares. We recently found that skin inflammation caused by…
Abstract Number: 1279 • ACR Convergence 2021
Impact of Active Lupus Nephritis in Patient-Reported Outcomes from a Latin American, Multicenter Lupus Cohort
Romina Nieto¹, Eduardo Ferreira Borba², Eugenia Settecasse³, Diana Fernandez-Avila⁴, Laura Maurelli⁵, Carla Gobbi⁶, Verónica Saurit⁷, Fernando Arizpe⁸, Julieta Daniele⁹, Maria Constanza Bertolaccini¹⁰, Eduardo Kerzberg¹¹, María de los Ángeles Gargiulo¹², Anabella Rodriguez¹³, Ana Carolina Londe¹⁴, Vitalina Sousa Barbosa¹⁵, Andrese Aline Gasparin¹⁶, Carolina Albanez A Cunha Andrade¹⁷, Luciana Parente Costa Seguro¹⁸, Lucas Victoria de Oliveira Martins¹⁹, Oscar Neira²⁰, Carolina Llanos²¹, Loreto Massardo²², Antonio Iglesias²³, Ivana Nieto Aristizábal²⁴, Gloria Vasquez²⁵, Paul Mendez-Patarroyo²⁶, Lizeth de la Hoz Rueda²³, José Martínez Pérez²⁷, Reyna Sánchez Briones²⁸, Mario Pérez Cristóbal²⁹, Eduardo Martin-Nares³⁰, Yaneli Juárez-Vicuña³¹, Yelitza Gonzalez Bello³², Jorge González García³³, Dionicio Galarza-Delgado³⁴, Marcos Vázquez³⁵, Patricia Langjarh³⁵, Magaly Alva Linares³⁶, Cristina Reategui-Sokolova³⁷, Armando Calvo Quirós³⁸, Edral Rodriguez³⁹, Ricardo Robaina⁴⁰, Martín Rebella⁴¹, Graciela Alarcn⁴², Ashley Orillion⁴³, Chetan Karyekar⁴⁴, Federico Zazzetti⁴⁵ and Guillermo Pons-Estel⁴⁶, ¹Hospital Provincial de Rosario, Rosario, Argentina, ²Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brazil, ³Instituto de Investigaciones Teóricas y Aplicadas. Facultad de Ciencias Económicas y Estadistica. Universidad Nacional de Rosario, Rosario, Argentina, ⁴Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁵Hospital Italiano de Córdoba, Córdoba, Argentina, ⁶Hospital Córdoba, Córdoba, Argentina, ⁷Hospital Privado Universitario de Córdoba, Córdoba, ⁸Hospital HIGA San Martín, La Plata, Argentina, ⁹Sanatorio Británico, Rosario, Argentina, ¹⁰Hospital Padilla, San Miguel de Tucumán, Argentina, ¹¹Hospital General de Agudos J.M. Ramos Mejía, Buenos Aires, Argentina, ¹²Instituto de Investigaciones Médicas Alfredo Lanari, Buenos Aires, Argentina, ¹³CEMIC, Buenos Aires, Argentina, ¹⁴Universidade Estadual de Campinas, Faculdade de Ciencias Médicas, São Paulo, Brazil, ¹⁵Hospital das Clinicas, Univerisad Federal de Goias, Goias, Brazil, ¹⁶Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil, ¹⁷Universidad Federal de Pernambuco, Recife, Brazil, ¹⁸Hospital Das Clinicas da Faculdade de Medicina da USP, São Paulo, Brazil, ¹⁹Universidad Federal São Paulo, São Paulo, Brazil, ²⁰Hospital del Salvador, Santiago, Chile, ²¹Facultad de Medicina, Pontificia Universidad Catolica de Chile, Santiago, Chile, ²²Universidad San Sebastián, Santiago, Chile, ²³Clínica de la Costa Ltda., Barranquilla, Colombia, ²⁴Fundación Valle del Lili, Cali, Colombia, ²⁵Division of rheumatology, Universidad de Antioquia, Medellin, Colombia, ²⁶Reumavance Group, Rheumatology section, Department of Internal Medicine, Fundación Santa Fe de Bogotá University Hospital; Department of Internal Medicine, School of Medicine, Universidad de Los Andes, Bogota, Colombia, ²⁷Hospital Luis Vernaza, Guayaquil, Ecuador, ²⁸Centro Médico La Raza, Ciudad de México, Mexico, ²⁹Centro Médico Nacional Siglo XXI, Ciudad de México, Mexico, ³⁰Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ³¹Instituto Nacional de Cardiología Ignacio Chávez, Ciudad de México, Mexico, ³²Centro de Estudios de investigación Básica y Clínica S.C, Guadalajara, Mexico, ³³Hospital Central Dr. Ignacio Morones Prieto, San Luís Potosí, Mexico, ³⁴Hospital Universitario "Dr Jose E. Gonzalez", Monterrey, Mexico, ³⁵Hospital de Clínicas I, Asunción, Paraguay, ³⁶Hospital Nacional Edgardo Rebagliatti Martins, Lima, Peru, ³⁷Hospital Guillermo Almenara Irigoyen, Lima, Peru, ³⁸Hospital Cayetano Heredia, Lima, Peru, ³⁹Hospital Docente Padre Billini, Santo Domingo, Dominican Republic, ⁴⁰Clínica Médica C, Hospital de Clínicas, UDELAR, Montevideo, Uruguay, ⁴¹Unidad de Enfermedades Autoinmunes Sistémicas de Médica Uruguay Corporación de Asistencia Médica (MUCAM); Unidad de Enfermedades Autoinmunes Sistémicas del Hospital de Clínicas, Facultad de Medicina, Universidad de la República, Montevideo, Uruguay, ⁴²University of Alabama at Birmingham, Birmingham, AL, ⁴³Global Commercial Strategic Organisation, Johnson and Johnson, Horsham, PA, ⁴⁴Janssen R&D, Spring House, PA, ⁴⁵Medical Affairs, Jan-Cil Argentina, Buenos Aires, Argentina, ⁴⁶Grupo Oroño. Centro Regional de Enfermedades Autoinmunes y Reumaticas (GO-CREAR), Rosario, Argentina
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by multiple and heterogeneous clinical manifestations that may negatively affect these patients’ quality of life…
Abstract Number: 1736 • ACR Convergence 2021
Treatment of Lupus Nephritis with Belimumab Is Associated with Reduction in Urinary CD23
Emma Weeding¹, Andrea Fava², Chandra Mohan³, Daniel Goldman⁴ and Michelle Petri⁴, ¹Johns Hopkins Hospital, Baltimore, MD, ²Johns Hopkins University, Baltimore, MD, ³University of Houston, Houston, TX, ⁴Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Urine proteomic approaches have shown promise in identifying dynamic biological pathways in lupus nephritis (LN) which are not captured on renal histopathology or by…
Abstract Number: 0454 • ACR Convergence 2021
Lupus Nephritis Mortality in the United States, 1999-2019: Profound Disparities by Race/Ethnicity and Place of Residence and a Recent Worsening Trend
Eric Yen¹, Snehin Rajkumar¹, Rohan Sharma¹ and Ram Singh², ¹University of California Los Angeles, Los Angeles, CA, ²University of California Los Angeles David Geffen School of Medicine, Los Angeles, CA
Background/Purpose: Mortality from SLE has improved over the last two decades, but remains disproportionately high relative to general population mortality. Lupus nephritis (LN) occurs in…
Abstract Number: 1280 • ACR Convergence 2021
Generation of Evidence Supporting the Content Validity of SF-36, Lupus-Qol, and FACIT-Fatigue, and Newly Developed Patient-reported Outcome (PRO) Symptom Items to Address Conceptual Gaps for Use in Patient with Lupus Nephritis
Rebecca Hall¹, Nicola Williamson¹, Melissa Barclay¹, Anna Roberts¹, Adam Gater¹, Chloe Tolley¹, Helena Bradley¹, Amy Ward¹, Patricia Delong², Elizabeth Hsia³, Qing Zuraw⁴, Zahi Touma⁵, Vibeke Strand⁶ and Pamela Berry², ¹Adelphi Values Ltd, Bollington, United Kingdom, ²Janssen Global Services, LLC, Horsham, PA, ³Janssen Research & Development, LLC, Spring House, PA, ⁴Janssen R&D, Wayne, PA, ⁵University of Toronto, Mississauga, ON, Canada, ⁶Stanford University School of Medicine, Portola Valley, CA
Background/Purpose: Lupus nephritis (LN) is an autoimmune disease characterized by inflammation of the kidneys, a severe manifestation of systemic lupus erythematosus (SLE) that occurs in…
Abstract Number: 1737 • ACR Convergence 2021
Reduction in Urinary CD163 Is Associated with Treatment Response in the Belimumab Lupus Nephritis Trial
Emma Weeding¹, Andrea Fava², Chandra Mohan³, Daniel Goldman⁴ and Michelle Petri⁴, ¹Johns Hopkins Hospital, Baltimore, MD, ²Johns Hopkins University, Baltimore, MD, ³University of Houston, Houston, TX, ⁴Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Urinary CD163 is a macrophage marker which correlates with histological activity index and response to treatment in lupus nephritis (LN), as evidenced by urine…
Abstract Number: 0470 • ACR Convergence 2021
Inhibition of Toll-Like Receptor 7 (TLR7) with the Potent and Selective Inhibitor of Human TLR7 and TLR8 BMS-986256 Provides Robust Efficacy in Murine Lupus Models, Reversing Established Disease
Shailesh Dudhgaonkar¹, Anjuman Rudra¹, Sourabh Ranade¹, Siva Subramani¹, Jignesh Nagar¹, Preethi Karunanithi¹, Priyadeep Bhutani¹, Vishwanath Kurawattimath¹, Rosemary Zhang², Hongchen Qiu², ALARIC DYCKMAN² and Gary Schieven², ¹Biocon Bristol Myers Squibb Research Center, Bangalore, India, ²Bristol Myers Squibb, Lawrenceville, NJ
Background/Purpose: TLR7, a member of the Toll-Like Receptor family, recognizes ssRNA and is primarily expressed in plasmacytoid dendritic cells and B cells. TLR7 has been…
Abstract Number: 1284 • ACR Convergence 2021
One Third of Lupus Nephritis Patients Classified as Complete Responders Continue to Accrue Progressive Renal Damage Despite Resolution of Proteinuria
Emma Weeding¹, Andrea Fava², Daniel Goldman³ and Michelle Petri³, ¹Johns Hopkins Hospital, Baltimore, MD, ²Johns Hopkins University, Baltimore, MD, ³Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Up to 40% of individuals with lupus nephritis (LN) develop chronic kidney disease (CKD). Biopsy studies have revealed that patients with SLE can have…
Abstract Number: 1744 • ACR Convergence 2021
Improvement of Renal and Non-Renal SLE Outcome Measures on Sirolimus Therapy – a 21-year Follow-up Study of 73 Patients
Paramarajan Piranavan¹ and Andras Perl², ¹SUNY Upstate Medical University, Syracuse, NY, ²State University of New York, Syracuse, NY
Background/Purpose: The clinical heterogeneity of the SLE makes it often challenging for the treating clinician and also remains one of the many reasons behind failed…
Abstract Number: 0472 • ACR Convergence 2021
An Atlas of Human and Mouse Intrarenal Immune Cells in Lupus Nephritis Reveals Homologous Immune Populations Across Common Mouse Strains and Species
Paul Hoover¹, Michael Peters², David Lieb², Runci Wang³, Garett Dunlap⁴, Deepak Rao¹, Nir Hacohen² and Anne Davidson⁵, ¹Brigham and Women's Hospital, Boston, MA, ²Broad Institute, Cambridge, MA, ³Brigham and Women’s Hospital, Boston, MA, ⁴Harvard University, Somerville, MA, ⁵Institute of Molecular Medicine, Feinstein Institutes for Medical Research, Manhasset, NY
Background/Purpose: We discovered 21 immune cell-types in lupus nephritis kidney biopsies as part of the Accelerating Medicines Partnership (AMP) consortium. These immune cells are the…
Abstract Number: 1289 • ACR Convergence 2021
Patients Enrolled in the Accelerating Medicines Partnership (AMP) RA/SLE Network with Isolated Renal Disease Report Minimal Quality of Life Impairment on PROMIS-29 Compared to Patients with Extrarenal Symptoms
Philip Carlucci¹, Jessica Li², Heather Gold³, Kristina Deonaraine¹, Andrea Fava², Jill Buyon⁴, Judith James⁵, Chaim Putterman⁶, Deepak Rao⁷, Betty Diamond⁸, Derek Fine², Jose Monroy-Trujillo², Kristin Haag⁹, Accelerating Medicines Partership (AMP) RA/SLE Network¹⁰, H. Michael Belmont⁴, Sean Connery¹¹, Fernanda Payan-Schober¹², Richard Furie¹³, Celine Berthier¹⁴, Maria Dall'Era¹⁵, Kerry Cho¹⁶, Diane Kamen¹⁷, Kenneth Kalunian¹⁸, The Accelerating Medicines Parternship In SLE Network¹⁹, Peter Izmirly¹ and Michelle Petri²⁰, ¹New York University School of Medicine, New York, NY, ²Johns Hopkins University, Baltimore, MD, ³NYU Grossman School of Medicine, New York, NY, ⁴NYU School of Medicine, New York, NY, ⁵Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁶Albert Einstein College of Medicine, Bronx, NY, ⁷Brigham and Women's Hospital, Boston, MA, ⁸Northwell Health, Manhasset, NY, ⁹Johns Hopkins School of Medicine, Baltimore, MD, ¹⁰Brigham and Women's Hospital, Everett, MA, ¹¹Texas Tech University Health Sciences Center, Texas, TX, ¹²Texas Tech University Health Sciences Center, El Paso, TX, ¹³Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, ¹⁴University of Michigan, Ann Arbor, MI, ¹⁵University of California San Francisco, Corte Madera, CA, ¹⁶University of California San Francisco, San Francisco, CA, ¹⁷Medical University of South Carolina, Charleston, SC, ¹⁸UC San Diego, La Jolla, CA, ¹⁹Multiple Institutions, Multiple Cities, ²⁰Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Lupus nephritis can occur as an isolated component of disease activity or be accompanied by diverse extrarenal symptoms that can adversely affect a patient’s…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].